Alfalasi Amani, Ameen Ahmed, Al Lafi Atlal, El Gendi Ayman, Saad Waqas, Ismail Ahmed, Al Naeem Ayman, Goturu Srikumar, Al-Ahmed Nasser, Dayem Hussein Abdel, Nanda Arti, Tawdy Amira, Alogayell Lulwa, Iraqi Mohamed, Abdul Hay Nasser, El Enezi Manar, Walkhinde Subash, Kamal Marwa, Aldhuhoori Muna, Almesfer Asem, Abd Elwhab Amira, Al Hawsawi Khalid Ali, Barakat Ahmad, Chmayse Sahar, Hafiz Mohammed, Chouikrat Zahir, Fahmy Monica
Department of Dermatology, Dubai Health, Dubai, United Arab Emirates (UAE).
Department of Dermatology, NMC Specialty Hospital, Abu Dhabi, UAE.
J Dermatolog Treat. 2025 Dec;36(1):2443110. doi: 10.1080/09546634.2024.2443110. Epub 2025 Jan 6.
PURPOSE/AIM OF THE STUDY: There is limited real-world evidence regarding the effectiveness and safety of dupilumab in Gulf countries. The study aimed to evaluate atopic dermatitis (AD) disease control in adult and adolescent patients (≥12 years) treated with dupilumab in Gulf countries.
This observational study included patients with moderate-to-severe AD who initiated dupilumab within 30 days. Disease control, itching/pruritus, and patient satisfaction were assessed using Scoring Atopic Dermatitis (SCORAD), AD Control Tool (ADCT), and Patient Global Assessment of Treatment Effect (PGATE) scores at weeks 4, 12, and 24.
The study included 187 participants with a mean age of 33.6 years. After 24 weeks, 75.1% of patients achieved disease control (ADCT score <7) compared to 4.3% at baseline ( < 0.001). Both ADCT and SCORAD scores significantly decreased from baseline scores (from 16.5 to 4.1 and 57.5 to 13.4, respectively, < 0.001). Also, patient satisfaction improved significantly, with 65.3% reporting "Very Good" or "Excellent" PGATE scores in the 24th week compared to 20.3% at the baseline ( < 0.001). The limitations are the small number of included patients and the lack of long-term safety data.
In conclusion, Dupilumab therapy is effective in controlling symptoms of moderate-to-severe AD patients in the Gulf countries. Most patients achieved high disease control and satisfaction levels.
关于度普利尤单抗在海湾国家的有效性和安全性，现实世界中的证据有限。本研究旨在评估海湾国家中接受度普利尤单抗治疗的成人和青少年患者（≥12岁）的特应性皮炎（AD）疾病控制情况。
这项观察性研究纳入了在30天内开始使用度普利尤单抗的中度至重度AD患者。在第4、12和24周时，使用特应性皮炎评分（SCORAD）、AD控制工具（ADCT）和患者对治疗效果的整体评估（PGATE）评分来评估疾病控制、瘙痒情况和患者满意度。
该研究纳入了187名参与者，平均年龄为33.6岁。24周后，75.1%的患者实现了疾病控制（ADCT评分<7），而基线时这一比例为4.3%（P<0.001）。ADCT和SCORAD评分均较基线评分显著降低（分别从16.5降至4.1和从57.5降至13.4，P<0.001）。此外，患者满意度显著提高，第24周时有65.3%的患者报告PGATE评分为“非常好”或“优秀”，而基线时这一比例为20.3%（P<0.001）。局限性在于纳入患者数量较少且缺乏长期安全性数据。
总之，度普利尤单抗疗法在控制海湾国家中度至重度AD患者的症状方面是有效的。大多数患者实现了较高的疾病控制水平和满意度。
